{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:54:24Z","timestamp":1777596864730,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejso.2018.07.047","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T12:31:01Z","timestamp":1533213061000},"page":"1486-1493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is\u00a0there a role in conjunction with conventional treatment?"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-372X","authenticated-orcid":false,"given":"Nicola","family":"de Liguori Carino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek A.","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajith K.","family":"Siriwardena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Radhakrishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rille","family":"Pihlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2018.07.047_bib1","author":"Cancer Research UK"},{"key":"10.1016\/j.ejso.2018.07.047_bib2","first-page":"h521","article-title":"Stage III pancreatic cancer and the role of irreversible electroporation","volume":"350","author":"Al Efishat","year":"2015","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.ejso.2018.07.047_bib3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","article-title":"Borderline resectable pancreatic cancer: a consensus statement by the international study group of pancreatic surgery (ISGPS)","volume":"155","author":"Bockhorn","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2018.07.047_bib4","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jamcollsurg.2012.05.021","article-title":"Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma","volume":"215","author":"Martin","year":"2012","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","article-title":"Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy","volume":"262","author":"Martin","year":"2015","journal-title":"Ann Surg"},{"issue":"Suppl 3","key":"10.1016\/j.ejso.2018.07.047_bib7","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1245\/s10434-012-2736-1","article-title":"Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival","volume":"20","author":"Martin","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib8","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jvir.2012.09.012","article-title":"Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma","volume":"23","author":"Narayanan","year":"2012","journal-title":"J Vasc Intervent Radiol: JVIR"},{"key":"10.1016\/j.ejso.2018.07.047_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jvir.2016.10.023","article-title":"Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma","volume":"28","author":"Narayanan","year":"2017","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.ejso.2018.07.047_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000375323","article-title":"Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study","volume":"32","author":"Paiella","year":"2015","journal-title":"Dig Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib11","first-page":"289","article-title":"Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer","volume":"34","author":"Mansson","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejso.2018.07.047_bib12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ejso.2016.01.024","article-title":"Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy","volume":"42","author":"Mansson","year":"2016","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2018.07.047_bib13","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ijsu.2015.06.049","article-title":"Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: our preliminary experience","volume":"21","author":"Belfiore","year":"2015","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib14","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1245\/s10434-015-5034-x","article-title":"Single-Institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients","volume":"23","author":"Kluger","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib15","first-page":"269","article-title":"Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience","volume":"63","author":"Lambert","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.ejso.2018.07.047_bib16","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.4103\/0366-6999.195476","article-title":"A single-institution experience with open irreversible electroporation for locally advanced pancreatic carcinoma","volume":"129","author":"Yan","year":"2016","journal-title":"Chinese Med J"},{"key":"10.1016\/j.ejso.2018.07.047_bib17","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/MPA.0000000000000703","article-title":"Percutaneous irreversible electroporation for ablation of locally advanced pancreatic cancer: experience from a Chinese institution","volume":"46","author":"Zhang","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.ejso.2018.07.047_bib18","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib19","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines) pancreatic adenocarcinoma version 2.2018","author":"National Comprehensive Cancer Network","year":"2018"},{"key":"10.1016\/j.ejso.2018.07.047_bib20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib22","author":"University of Liverpool (UK)"},{"key":"10.1016\/j.ejso.2018.07.047_bib23","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1245\/s10434-015-4647-4","article-title":"FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma","volume":"22","author":"Sadot","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2017.35.4_suppl.358","article-title":"Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)","volume":"35","author":"Lacy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib25","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib26","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2018.07.047_bib27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2018.07.047_bib28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib29","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.2004.12.082","article-title":"Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate","volume":"22","author":"Rocha Lima","year":"2004","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib30","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib31","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib33","series-title":"ClinicalTrials.gov [Internet]","article-title":"Neoadjuvant mFolfirinox with or without preoperative concomitant chemoradiotherapy in patients with borderline resectable pancreatic carcinoma (PANDAS-PRODIGE 44)","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies","volume":"25","author":"Huguet","year":"2007","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.22735","article-title":"Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy","volume":"110","author":"Krishnan","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2018.07.047_bib36","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol: Offic J Eur Soc Med Oncology ESMO"},{"key":"10.1016\/j.ejso.2018.07.047_bib37","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 Months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejso.2018.07.047_bib38","series-title":"ClinicalTrials.gov [Internet]","article-title":"Systemic therapy and chemoradiation in advanced localised pancreatic cancer - 2","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6604436","article-title":"Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses","volume":"99","author":"Sultana","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2018.07.047_bib40","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1200\/JCO.2008.19.7921","article-title":"Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ejso.2018.07.047_bib41","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol: Offic J Eur Soc Med Oncology ESMO"},{"key":"10.1016\/j.ejso.2018.07.047_bib42","doi-asserted-by":"crossref","first-page":"E204","DOI":"10.1016\/j.ijrobp.2017.06.1089","article-title":"The effect of increasing biologically effective dose in stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer: a meta-analysis","volume":"99","author":"Zaorsky","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejso.2018.07.047_bib43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejso.2018.07.047_bib44","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/j.ijrobp.2014.05.1186","article-title":"Surgical outcomes following chemotherapy and stereotactic body radiation therapy in patients with borderline and unresectable pancreatic cancer","volume":"90","author":"Moningi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejso.2018.07.047_bib45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/era.13.19","article-title":"Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer","volume":"13","author":"Berber","year":"2013","journal-title":"Expet Rev Anticancer Ther"},{"key":"10.1016\/j.ejso.2018.07.047_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/era.09.16","article-title":"Role of intensity-modulated radiation therapy in gastrointestinal cancer","volume":"9","author":"Bockbrader","year":"2009","journal-title":"Expet Rev Anticancer Ther"},{"key":"10.1016\/j.ejso.2018.07.047_bib47","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2018.07.047_bib48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.gassur.2004.09.046","article-title":"Pancreaticoduodenectomy with vascular resection: margin status and survival duration","volume":"8","author":"Tseng","year":"2004","journal-title":"J Gastrointest Surg: Offic J Soc Surg Aliment Tract"},{"key":"10.1016\/j.ejso.2018.07.047_bib49","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s00268-012-1461-z","article-title":"Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis","volume":"36","author":"Zhou","year":"2012","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/bjs.7270","article-title":"Arterial en bloc resection for pancreatic carcinoma","volume":"98","author":"Bockhorn","year":"2011","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hpb.2017.02.437","article-title":"Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review","volume":"19","author":"Jegatheeswaran","year":"2017","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ejso.2018.07.047_bib52","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/SLA.0b013e31823ac299","article-title":"Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis","volume":"254","author":"Mollberg","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-3495(90)82348-1","article-title":"Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy","volume":"58","author":"Chang","year":"1990","journal-title":"Biophys J"},{"key":"10.1016\/j.ejso.2018.07.047_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/153303460700600106","article-title":"Irreversible electroporation: a new ablation modality--clinical implications","volume":"6","author":"Rubinsky","year":"2007","journal-title":"Technol Canc Res Treat"},{"key":"10.1016\/j.ejso.2018.07.047_bib55","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1477-2574.2010.00174.x","article-title":"Irreversible electroporation of the pancreas in swine: a pilot study","volume":"12","author":"Charpentier","year":"2010","journal-title":"HPB: Offic J Int Hepato Pancreato Biliary Assoc"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2018.07.047_bib56","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.5009\/gnl.2010.4.S1.S99","article-title":"Irreversible electroporation: a novel image-guided cancer therapy","volume":"4","author":"Lee","year":"2010","journal-title":"Gut Liver"},{"key":"10.1016\/j.ejso.2018.07.047_bib57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jso.21899","article-title":"Irreversible electroporation of the pancreas: definitive local therapy without systemic effects","volume":"104","author":"Bower","year":"2011","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib58","doi-asserted-by":"crossref","first-page":"W330","DOI":"10.2214\/AJR.10.4490","article-title":"Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization","volume":"196","author":"Deodhar","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ejso.2018.07.047_bib59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1148\/radiol.2016152835","article-title":"Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: results of the phase I\/II PANFIRE study","volume":"282","author":"Scheffer","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.ejso.2018.07.047_bib60","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1245\/s10434-017-5900-9","article-title":"Induction chemotherapy followed by resection or irreversible electroporation in locally advanced pancreatic cancer (IMPALA): a prospective cohort study","volume":"24","author":"Vogel","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib61","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cam4.433","article-title":"Pancreatic cancer and FOLFIRINOX: a new era and new questions","volume":"4","author":"Marsh Rde","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejso.2018.07.047_bib62","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13566-013-0115-6","article-title":"Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor\u2013vessel relationships","volume":"2","author":"Dholakia","year":"2013","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib64","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/00365521.2017.1346705","article-title":"The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy","volume":"52","author":"Ansari","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ejso.2018.07.047_bib65","series-title":"ClinicalTrials.gov [Internet]","article-title":"Comparing the efficacy of irreversible electroporation with radiotherapy","author":"CROSSFIRE Trial","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib66","series-title":"ClinicalTrials.gov [Internet]","article-title":"Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib67","series-title":"ClinicalTrials.gov [Internet]","article-title":"Combination of irreversible electroporation and NK immunotherapy for advanced pancreatic cancer","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib68","series-title":"ClinicalTrials.gov [Internet]","article-title":"Outcomes of ablation of unresectable pancreatic cancer using the NanoKnife irreversible electroporation (IRE) system","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib69","series-title":"ClinicalTrials.gov [Internet]","article-title":"A study of the use of irreversible electroporation in pancreatic ductal cancer","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib70","series-title":"ClinicalTrials.gov [Internet]","article-title":"Irreversible electroporation (NanoKnife) for the treatment of pancreatic adenocarcinoma","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib71","series-title":"ClinicalTrials.gov [Internet]","article-title":"Pancreatic irreversible electroporation (IRE) registry","author":"American Hepato-Pancreato-Biliary Association (AHPBA)","year":"2000"},{"key":"10.1016\/j.ejso.2018.07.047_bib72","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ejso.2018.07.047_bib73","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/bjc.2017.95","article-title":"Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer","volume":"116","author":"Hurt","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2018.07.047_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12957-016-0767-y","article-title":"A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma","volume":"14","author":"Satoi","year":"2016","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2018.07.047_bib75","article-title":"The role of staging laparoscopy in resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis","author":"Ta","year":"2018","journal-title":"Dig Surg"},{"key":"10.1016\/j.ejso.2018.07.047_bib76","author":"National Institute for Health and Care Excellence"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798318312496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798318312496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:26:56Z","timestamp":1760059616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798318312496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":76,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0748798318312496"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2018.07.047","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is\u00a0there a role in conjunction with conventional treatment?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2018.07.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}